Katja Werlenius

Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Radiotherapy quality assurance in the PRO-GLIO trial: results from a dummy run comparing experts across twelve institutions in two Scandinavian countries.

Radiotherapy quality assurance in the PRO-GLIO trial: results from a dummy run comparing experts across twelve institutions in two Scandinavian countries.

Journal: Clinical and translational radiation oncology

Published: May 03, 2026

MGMT promoter methylation status for glioblastoma: defining the clinically relevant cut-off value for pyrosequencing.

MGMT promoter methylation status for glioblastoma: defining the clinically relevant cut-off value for pyrosequencing.

Journal: Journal of neuro-oncology

Published: April 22, 2026

Case Report: Proton beam therapy - friend or foe for patients with IDH-mutated WHO grade 2 and 3 gliomas?

Case Report: Proton beam therapy - friend or foe for patients with IDH-mutated WHO grade 2 and 3 gliomas?

Journal: Frontiers in oncology

Published: February 04, 2026

Unexpected frequency of radiation induced contrast enhancement after proton radiotherapy in glioma patients treated within the Swedish PRO-CNS study.

Unexpected frequency of radiation induced contrast enhancement after proton radiotherapy in glioma patients treated within the Swedish PRO-CNS study.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: December 05, 2025

Case report: Pseudoprogression mimicking neoplastic recurrence three months after completion of proton beam therapy for an IDH-mutant astrocytoma CNS WHO grade 3.

Case report: Pseudoprogression mimicking neoplastic recurrence three months after completion of proton beam therapy for an IDH-mutant astrocytoma CNS WHO grade 3.

Journal: Frontiers in oncology

Published: March 08, 2024

What predicts survival in glioblastoma? A population-based study of changes in clinical management and outcome.

What predicts survival in glioblastoma? A population-based study of changes in clinical management and outcome.

Journal: Frontiers in surgery

Published: June 28, 2023

Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma: A Randomized Clinical Trial.

Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma: A Randomized Clinical Trial.

Journal: JAMA network open

Published: March 31, 2023

Investigating survival, quality of life and cognition in PROton versus photon therapy for IDH-mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden.

Investigating survival, quality of life and cognition in PROton versus photon therapy for IDH-mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden.

Journal: BMJ open

Published: March 20, 2023

Changes in clinical management of diffuse IDH-mutated lower-grade gliomas: patterns of care in a 15-year period.

Changes in clinical management of diffuse IDH-mutated lower-grade gliomas: patterns of care in a 15-year period.

Journal: Journal of neuro-oncology

Published: August 19, 2022

A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma.

A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma.

Journal: Neuro-oncology advances

Published: November 12, 2021

Patterns of care and clinical outcome in assumed glioblastoma without tissue diagnosis: A population-based study of 131 consecutive patients.

Patterns of care and clinical outcome in assumed glioblastoma without tissue diagnosis: A population-based study of 131 consecutive patients.

Journal: PloS one

Published: October 18, 2019

Disulfiram repurposing combined with nutritional copper supplement as add-on to chemotherapy in recurrent glioblastoma (DIRECT): Study protocol for a randomized controlled trial.

Disulfiram repurposing combined with nutritional copper supplement as add-on to chemotherapy in recurrent glioblastoma (DIRECT): Study protocol for a randomized controlled trial.

Journal: F1000Research

Published: October 30, 2018

Showing 1-12 of 17

Last Updated: 09/26/2026